Investment Summary |
|
|---|---|
| Date | 2022-03-28 |
| Target | Aculys Pharma |
| Sector | Life Science |
| Investor(s) | HBM Partners AG |
| Deal Type | Venture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.0B USD |
| Size | Mega |
| Type | Sector Focused |
HBM Partners is a private investment firm focused on investing in entrepreneurial biopharma and other healthcare-related companies in Europe, North America, India and other Emerging Markets. HBM looks to invest $5 to $50 million per transaction and will consider private and public companies. HBM Partners was established in 2001 and is headquartered in Zug, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 65 of 66 |
| Sector (Life Science) | 56 of 57 |
| Type (Venture) | 52 of 53 |
| Country (Japan) | 1 of 1 |
| Year (2022) | 2 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-02-07 |
1000Farmacie
Napoli, Italy 1000Farmacie is an Italian e-pharmacy and digital healthcare platform with a vision to improve healthcare services and medicine delivery to customers and patients. 1000Farmacie’s pharmacy marketplace offers a wide range of products and services at the best cost via its network of independent pharmacies. 1000Farmcie was founded in 2020 and is based in Napoli, Italy. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-06-03 |
Turning Point Therapeutics
San Diego, California, United States Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectini, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Turning Point Therapeutics was formed in 2013 and is based in San Diego, California. |
Sell | $4.1B |
